These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12773968)

  • 21. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclizumab: a review of its use in the management of organ transplantation.
    Carswell CI; Plosker GL; Wagstaff AJ
    BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review.
    Sandrini S
    Clin Transplant; 2005 Dec; 19(6):705-10. PubMed ID: 16313313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 27. Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen.
    Sampaio MS; Poommipanit N; Kuo HT; Reddy PN; Cho YW; Shah T; Bunnapradist S
    Pediatr Transplant; 2010 Sep; 14(6):770-8. PubMed ID: 20477974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic strategy for acute rejection in organ transplantation--optimal use of monoclonal antibody].
    Hanafusa T; Takahara S
    Nihon Rinsho; 2002 Mar; 60(3):598-602. PubMed ID: 11904979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials.
    Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    J Heart Lung Transplant; 2008 Aug; 27(8):835-42. PubMed ID: 18656795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
    Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
    Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study.
    Xue M; Lv C; Chen X; Huang X; Sun Q; Wang T; Liang J; Zhang Y; He S; Gao J; Zhou J; Yu M; Fan J; Gao X
    J Diabetes; 2016 Jul; 8(4):579-87. PubMed ID: 26588180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
    Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
    Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of antibodies against the IL-2 receptor in transplantation.
    Waldmann TA; O'Shea J
    Curr Opin Immunol; 1998 Oct; 10(5):507-12. PubMed ID: 9794841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.
    Schachter AD; Meyers KE; Spaneas LD; Palmer JA; Salmanullah M; Baluarte J; Brayman KL; Harmon WE
    Pediatr Transplant; 2004 Apr; 8(2):171-7. PubMed ID: 15049798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction.
    Cantarovich M; Metrakos P; Giannetti N; Cecere R; Barkun J; Tchervenkov J
    Transplantation; 2002 Apr; 73(7):1169-72. PubMed ID: 11965054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation.
    Ciancio G; Mattiazzi A; Miller J; Burke GW
    Minerva Urol Nefrol; 2003 Mar; 55(1):43-56. PubMed ID: 12773966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of interleukin-2 receptor antagonists in solid organ transplantation.
    Berard JL; Velez RL; Freeman RB; Tsunoda SM
    Pharmacotherapy; 1999 Oct; 19(10):1127-37. PubMed ID: 10512062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.